PRE-MARKET | October 21, 2016 | $MSFT, $PYPL, $MCD, $SAP, $BABA, $AMGN, $TWTR, $TWLO, $AMD

PRE-MARKET MOVERS

1. ALKS: $ALKS Alkermes Depression Drug Finds Success on Third Study Attempt – Adam Feuerstein

2. ALKS, CERC:  $CERC Cerecor Surges with Alkermes $ALKS Following Positive Depression Trial Results – Street Insider

3. RAI:  $RAI BAT Offers to Buy Rest of Reynolds American for $47 Billion – BBG

4. PFPT:  $PFPT Proofpoint Q3 Swings To Profit, Revenue Jumps 44%; Stock Jumps – IBD

5. MSFT:  $MSFT Microsoft Shares Hit a High With Promise of the Cloud’s Profit Margins – NYTimes

6. VRSN:  $VRSN Verisign Inc. Reports Amendments to Agreements with DOC, ICANN – Street Insider

7. PYPL:  $PYPL PayPal Revenue Climbs on Growing Active Accounts – WSJ

8. COH:  $COH Burberry Gains After Report Coach Is Considering Merger – BBG

9. MCD:  $MCD McDonald’s 3Q Earnings Beat Expectations – Fox Biz

10. APOL:  $APOL Apollo Education Swings to Profit – WSJ

11. KLAC:  $KLAC KLA-Tencor Stock Advances in After-Hours Trading on Q1 Beat – TheStreet

12. SAP:  $SAP SAP Raises Sales, Profit Forecast on Improved Cloud Outlook – BBG

13. ETFC:  $ETFC E*Trade swings to profit on OptionsHouse deal – MarketWatch

14. MRK:  $MRK Merck’s Keytruda succeeds in key bladder cancer trial – Reuters

15. PTCT:  $PTCT PTC Therapeutics Commences RG7916 Phase 2 in Type 2/3 SMA Patients with Roche, SMAF – SI

23. ENDP: $ENDP CFO leaving Endo International Plc – Reuters

24. TWTR:  $TWTR No partner in sight, Twitter faces tough solo choices – Reuters

25. GE:  $GE General Electric cut its revenue forecast – Business insider

26. DXPE:  $DXPE DXP Enterprises Starts Shares Offering, Initial Q3 Data Weak – Zacks

27. ATHN:  $ATHN athenahealth Tops Q3 EPS by 13c; Forges New Partnership with Tandigm Health – Street Insider

28. MCO:  $MCO Moody’s Corp. Tops Q3 EPS by 16c; Update FY16 EPS Outlook; Offers Litigation Update – SI

29. IHG:  $IHG InterContinental Hotels Falls as Room Revenue Growth Rate Slows – BBG

30. LZB:  $LZB La-Z-Boy sharply lowers quarterly outlook – MarketWatch

31. SAM:  $SAM Boston Beer cuts projections further – Market Watch

32. AMD:  $AMD Advanced Micro Devices, Inc. Tumbles After Posting Loss – ValueWalk

33. ERIC:  $ERIC Ericsson Posts First Net Loss in Four Years as Demand Wanes – BBG

34. RRGB:  $RRGB Red Robin Gourmet Burgers Is Pulling Back On Q3 Forecast – RTT

35. TWLO:  $TWLO Twilio Announces Pricing of Follow-on Public Offering – BusinessWire

36. SKX:  $SKX Skechers shares tumble as earnings and outlook lag estimates – MarketWatch

37. SGY:  $SGY Stone Energy’s stock plunges as RSA agreement contemplates bankruptcy – MarketWatch

UPGRADES

DOWNGRADES

EARNINGS

1. ERIC:$ERIC reports FQ3 earnings of 4c EPS and $5.62B Revs –

2. STI:$STI reports FQ3 earnings of 91c EPS and $2.23B Revs –

3. STI:$STI reports inline with the Estimize EPS Consensus and beats the Estimize Revenue Consensus by $65.47M –

4. HON:$HON reports FQ3 earnings of $1.67 EPS and $9.80B Revs –

5. GE:$GE reports FQ3 earnings of 32c EPS and $29.17B Revs –

6. SYF:$SYF reports FQ3 earnings of 73c EPS and $3.48B Revs –

7. MCO:$MCO reports FQ3 earnings of $1.34 EPS and $917.10M Revs –

8. N:$N reports FQ3 earnings of 20c EPS and $243.92M Revs –

Trending Social Alerts

Trending News Headlines

KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. “The results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,” said Dr. Roger M. Perlmutter , president, Merck Research Laboratories . “We look forward to sharing the findings from this study with the medical community and with regulatory

The apparent lack of interest in Twitter Inc by potential suitors may force the social media company to consider a route anathema to aspiring tech startups: a major restructuring and cutting some its nearly 4,000 employees.

Technology News

Today’s Economic Calendar
10:15 Daniel Tarullo speech
1:00 PM Baker-Hughes Rig Coun

If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel

See you in the chat room